Dying to serve: Dozens of recruits have died nationwide while training to become police officers
Ronald Donat’s longtime dream of becoming a police officer was in jeopardy. The 41-year-old struggled to stand after ...
Anemia Treatment Market Poised For Strong Growth, Expected To Hit USD 19.1 Billion By 2033
Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...
WRIC on MSN3d
Dozens of police recruits nationwide have died while training in last decade: probe
At least 29 recruits died during basic training at law enforcement academies around the country in the last decade, an AP ...
Detroit News3d
Dying to serve: Dozens of recruits have died nationwide while training to become police officers
Many carried sickle cell trait, a condition most prevalent among ... It requires trainers be educated on heat exhaustion, dehydration and symptoms of sudden cardiac arrest, and mandates that ...
Flow Space on MSN2d
Black Women Leading the Charge in Healthcare: Meet 3 Pioneering Doctors Tackling Disparities
These physicians have dedicated their careers to fighting for health equity, ensuring that quality care isn't just a ...
Harvard Medical School1d
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
WCIV Charleston on MSN3d
Gene therapy among cutting-edge treatments at MUSC's new sickle cell center in Charleston
The Medical University of South Carolina Health has established the Rena N. Grant Sickle Cell Center to help treat those ...
emjreviews.com16h
Sickle Cell Trait Not Linked to Exertion-Related Death, Study Finds
A SYSTEMATIC review by the American Society of Hematology (ASH) has found no evidence to support sickle cell trait (SCT) as a cause of acute pain crises or sudden exertion-related death. This finding ...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.